Puma Biotechnology
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2010-01-01
- Employees
- 185
- Market Cap
- $124.5M
- Introduction
Puma Biotechnology, Inc. is a biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. It focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial ...
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology announced a restricted stock unit award for a new non-executive employee, vesting over three years under the 2017 Employment Inducement Incentive Award Plan. The company focuses on cancer care, with products like NERLYNX® for HER2-positive breast cancer and alisertib for small cell lung cancer.
Puma Biotechnology Reports Inducement Awards
Puma Biotechnology (NASDAQ: PBYI) approved a 5,625-share inducement restricted stock unit award for a new non-executive employee, vesting over three years starting Nov 1, 2024, under the 2017 Employment Inducement Incentive Award Plan, in compliance with Nasdaq Listing Rule 5635(c)(4).
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Puma
Kaskela Law LLC investigates Puma Biotechnology, Inc. (NASDAQ: PBYI) for shareholders. Puma's stock has declined over 58% since February 2024, from $7.25 to under $3.00 per share. The investigation aims to determine if Puma and its officers/directors violated securities laws or breached fiduciary duties.
Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results
Puma Biotechnology will host a conference call on Nov 7, 2024, at 1:30 p.m. PST/4:30 p.m. EST following Q3 2024 financial results release. The call will be accessible via phone or webcast on their website, with a replay available for 90 days.
© Copyright 2024. All Rights Reserved by MedPath